Scarica l'app Stockscreener
4.71
8.11%
0.30
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.41
Aprire:
$4.4
Volume 24 ore:
54,548
Relative Volume:
0.75
Capitalizzazione di mercato:
$52.29M
Reddito:
$1.93M
Utile/perdita netta:
$-7.96M
Rapporto P/E:
-0.00133
EPS:
-3530.8178
Flusso di cassa netto:
$-36.78M
1 W Prestazione:
-2.70%
1M Prestazione:
-37.76%
6M Prestazione:
-58.83%
1 anno Prestazione:
-60.95%
Intervallo 1D:
$4.40
$4.77
Intervallo di 1 settimana:
$4.15
$5.0883
Portata 52W:
$4.15
$17.49
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Nome
Avalo Therapeutics Inc
Settore
Industria
Telefono
410-522-8707
Indirizzo
540 GAITHER ROAD, ROCKVILLE
Confronta AVTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
4.67 | 52.29M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.61 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.39 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.96 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.16 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.72 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-25 | Iniziato | Jefferies | Buy |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-28 | Iniziato | Piper Sandler | Overweight |
| 2025-02-21 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-10-24 | Iniziato | H.C. Wainwright | Neutral |
| 2024-04-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
60,000 Shares in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Purchased by Bank of Montreal Can - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $33.00 Average PT from Brokerages - Defense World
Avalo Therapeutics (AVTX) Sees New Options Listings for April | - GuruFocus
Avalo Therapeutics (AVTX) Sees New Options Listings for April | AVTX Stock News - GuruFocus
Seven new option listings and one option delisting on April 16th - TipRanks
Avalo Therapeutics Reports 2024 Financial Results - TipRanks
(AVTX) On The My Stocks Page - news.stocktradersdaily.com
AVTX stock touches 52-week low at $5.98 amid market challenges - Investing.com Australia
AVTX stock touches 52-week low at $5.98 amid market challenges By Investing.com - Investing.com South Africa
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Stifel Nicolaus - MarketBeat
Avalo Therapeutics (AVTX) to Release Earnings on Friday - Defense World
Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00 - Defense World
Avalo Therapeutics names new Chairman amid growth phase By Investing.com - Investing.com South Africa
Avalo Therapeutics Names Michael Heffernan as Board Chairman - MarketScreener
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board - MarketScreener
Avalo Therapeutics names new Chairman amid growth phase - Investing.com
DynaCERT And Avalo Therapeutics Poised For Growth - Evrim Ağacı
Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel initiates Avalo Therapeutics stock with a Buy rating By Investing.com - Investing.com Australia
Jefferies Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside - Benzinga
Jefferies starts Avalo stock with Buy, sets $23 price target By Investing.com - Investing.com Australia
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Stifel Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Stifel Initiates Avalo Therapeutics at Buy With $36 Price Target - MarketScreener
How the (AVTX) price action is used to our Advantage - news.stocktradersdaily.com
Jefferies starts Avalo stock with Buy, sets $23 price target - Investing.com
Stifel initiates Avalo Therapeutics stock with a Buy rating - Investing.com India
Oppenheimer maintains Avalo stock Outperform with $35 target By Investing.com - Investing.com Canada
Oppenheimer maintains Avalo stock Outperform with $35 target - Investing.com
Equities Analysts Set Expectations for AVTX Q1 Earnings - Defense World
Wedbush Research Analysts Lift Earnings Estimates for AVTX - Defense World
Wedbush Forecasts Increased Earnings for Avalo Therapeutics - The AM Reporter
HC Wainwright Reiterates Neutral Rating for Avalo Therapeutics (NASDAQ:AVTX) - Defense World
Q1 EPS Estimates for Avalo Therapeutics Boosted by Wedbush - Defense World
Avalo Reports 2024 Financial Results and Recent Business Updates - GlobeNewswire
Avalo Therapeutics Reports Business Updates and Financial Results for 2024, Highlights Phase 2 LOTUS Trial Progress for AVTX-009 in Hidradenitis Suppurativa - Nasdaq
Avalo Therapeutics, Inc. SEC 10-K Report - TradingView
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - Defense World
AVTX’s 52-Week Rollercoaster: From $4.35 to $34.46 – What’s Next for Investors? - The InvestChronicle
PSTV Rallies, TOVX Gears Up For VIRAGE Trial Data, Will AVTX's LOTUS Bloom? - RTTNews
(AVTX) Investment Analysis - Stock Traders Daily
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Piper Sandler - Defense World
Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - Nasdaq
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga India
Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target -February 28, 2025 at 07:54 am EST - Marketscreener.com
Piper Sandler sets $48 target on Avalo Therapeutics stock - Investing.com
Avalo Therapeutics (NASDAQ:AVTX) Upgraded by Wedbush to "Strong-Buy" Rating - MarketBeat
Avalo Therapeutics Inc Azioni (AVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):